Analgesia News and Research RSS Feed - Analgesia News and Research

Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

Pacira Pharmaceuticals, Inc. today announced data demonstrating the benefits associated with the use of EXPAREL (bupivacaine liposome injectable suspension) in a study of over 2,200 hip and knee replacement patients. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions. [More]
AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
Study suggests distinct role of brain regions in dental pain relief

Study suggests distinct role of brain regions in dental pain relief

Today at the 93rd General Session and Exhibition of the International Association for Dental Research, researcher Michael L. Meier, Center for Dental Medicine, University of Zürich, Switzerland, will present a study titled "Distinct Brain Mechanisms Related to Dental Pain Relief." [More]
Kaleo, CHMI partner to reduce prescription drug-related deaths

Kaleo, CHMI partner to reduce prescription drug-related deaths

Kaleo, a privately-held pharmaceutical company, today announced a national strategic partnership with the Clinton Health Matters Initiative, an initiative of the Clinton Foundation, that will help support its goal of cutting prescription drug-related deaths in half, saving approximately 10,000 lives over five years. [More]
Secrets of success for pioneering research revealed

Secrets of success for pioneering research revealed

The British Pharmacological Society has announced the secrets of success for pioneering research along with the outcome of its annual 'Putting UK Pharmacology on the Map' vote. The vote selects sites of special scientific interest linked to achievements in pharmacology based on a ballot of MPs, peers and senior members of the scientific community. [More]
AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device. [More]
New data shows EXPAREL provides effective pain control following total knee arthroplasty

New data shows EXPAREL provides effective pain control following total knee arthroplasty

Pacira Pharmaceuticals, Inc. today announced results of an independent, physician-initiated study designed to evaluate the difference in postsurgical pain and opioid consumption between patients who received EXPAREL versus a multi-drug analgesic cocktail for pain management following total knee arthroplasty (TKA). [More]
Hospira launches Paricalcitol Injection

Hospira launches Paricalcitol Injection

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1. [More]
Cogent OA teams up with Medpharm Publications to co-publish society-affiliated journals

Cogent OA teams up with Medpharm Publications to co-publish society-affiliated journals

Cogent OA is delighted to announce a partnership with Medpharm Publications of South Africa to co-publish several of its society-affiliated journals, providing leading online functionality and marketing services to further increase visibility and global reach. [More]
Union Hospital expands use of capnography to strengthen patient safety

Union Hospital expands use of capnography to strengthen patient safety

Union Hospital recently strengthened patient safety measures by expanding its use of capnography to monitor patients capnography during patient-controlled analgesia (PCA) to regulate their pain after surgery. [More]
Henrik Kehlet recognized with ASA's 2014 Excellence in Research Award

Henrik Kehlet recognized with ASA's 2014 Excellence in Research Award

The American Society of Anesthesiologists today presented Henrik Kehlet, M.D., Ph.D., with its 2014 Excellence in Research Award in recognition of his outstanding contributions to research which have had an important impact on anesthesiology as a medical specialty. [More]
Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery). [More]
Depression contributes to abnormal pain processes in IBS patients

Depression contributes to abnormal pain processes in IBS patients

High rates of anxiety and depression amongst patients with irritable bowel syndrome (IBS) have led many researchers to believe there could be a causal relationship between psychological factors and IBS symptoms. Now, scientists in Germany have found clear evidence that patients with IBS process pain signals from the gut abnormally, and that disturbed brain responses to pain are particularly pronounced in patients with more depression symptoms. [More]
AcelRx plans for resubmission of Zalviso NDA

AcelRx plans for resubmission of Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update on the plans for the resubmission of the Company's New Drug Application (NDA) for Zalviso (sufentanil sublingual tablet system). [More]

Desaturation 'area under the curve' may help in monitoring patient safety during procedures

The "area under the curve of oxygen desaturation" (AUCDesat) may provide a more sophisticated approach to monitoring blood oxygen levels during procedures using sedation, according to a study published in Anesthesia & Analgesia. [More]
Epidurals and reduced postpartum depression: an interview with Dr. Zakowski

Epidurals and reduced postpartum depression: an interview with Dr. Zakowski

The “maternity blues”, which resolve within 10 days of giving birth, occurs in up to 80% of new moms. A major depressive episode, by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, is defined as having at least a 2-week period of persistent depressed mood ... [More]
Catecholamine polymorphism influences opioid use

Catecholamine polymorphism influences opioid use

The catechol-O-methyltransferase rs4680 single nucleotide polymorphism could affect postoperative opioid consumption, study findings show. [More]
Advertisement
Advertisement